Elinor Karlsson to Biomarkers, Tumor
This is a "connection" page, showing publications Elinor Karlsson has written about Biomarkers, Tumor.
Connection Strength
0.845
-
Karlsson E, Magic I, Bostner J, Dyrager C, Lysholm F, Hallbeck AL, St?l O, Lundstr?m P. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis. PLoS One. 2015; 10(12):e0145013.
Score: 0.382
-
Karlsson E, Waltersson MA, Bostner J, P?rez-Tenorio G, Olsson B, Hallbeck AL, St?l O. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer. 2011 Oct; 50(10):775-87.
Score: 0.281
-
Karlsson E, Veenstra C, G?rsj? J, Nordenskj?ld B, Fornander T, St?l O. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer. J Cancer Res Clin Oncol. 2019 Mar; 145(3):599-607.
Score: 0.117
-
Veenstra C, P?rez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordensk?ljd B, Fornander T, St?l O. Met and its ligand HGF are associated with clinical outcome in breast cancer. Oncotarget. 2016 Jun 14; 7(24):37145-37159.
Score: 0.025
-
Bojmar L, Karlsson E, Elleg?rd S, Olsson H, Bj?rnsson B, Hallb??k O, Larsson M, St?l O, Sandstr?m P. The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One. 2013; 8(12):e84815.
Score: 0.021
-
Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskj?ld B, St?l O. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat. 2013 Jan; 137(2):397-406.
Score: 0.019